Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Currency in USD	2025
Operating Income	44.80 Million
Income Before Tax	66.46 Million
Income Tax Expense	-33.19 Million
Net Income	99.65 Million
Eps	0.95
Epsdiluted	0.82
Weighted Average Shs Out	103.86 Million
Weighted Average Shs Out Dil	119.99 Million
Research And Development Expenses	254.91 Million
Selling General And Administrative Expenses	448.73 Million
Depreciation And Amortization	1.15 Million
Interest Expense	N/A
Interest Income	21.67 Million
Net Interest Income	21.67 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	748.43 Million
Ebitda	45.95 Million
Source	edgar
Ebit	44.80 Million

Corcept Therapeutics Incorporated Annual Reports (10-K)